Friday 23 May, 2025 04:58 PM
Site map | Locate Us | Login
   Kirloskar Inds gains after Q4 PAT climbs 95% QoQ to Rs 47 cr    Shilpa Medicare zooms as arm partners with Orion Corporation    AIA Engineering gains after Q4 PAT rises 10% QoQ to Rs 285 crore    Alembic Pharma receives USFDA nod for Amlodipine and Atorvastatin Tablets    Bharti Airtel Ltd Partly Paidup leads losers in 'A' group    Dhabriya Polywood soars as Q4 PAT jumps 32% YoY to Rs 5 crore    Devyani Intl Q4 net loss widens to Rs 15 cr    Premier Explosives Ltd leads losers in 'B' group    Premier Explosives drops after weak Q4 numbers    Greenpanel Inds Q4 PAT falls 1% YoY to Rs 29 crore    Volumes spurt at Honasa Consumer Ltd counter    BEML gains as Q4 PAT jumps 12% YoY to Rs 288 cr    Healthcare shares slide    Sun Pharma drops after Q4 PAT slides 19% YoY to Rs 2,1450 cr    Mankind Pharma Ltd slips for fifth straight session 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Alembic Pharma gains after receiving EIR from USFDA for Panelav facility
30-Apr-25   13:17 Hrs IST

The company announced in an exchange filing that the EIR pertains to an inspection conducted by the USFDA at its Oncology Formulation Facility (F-2), which includes both injectable and oral solid formulations. The inspection was carried out from 7 October 2024 to 8 October 2024.

In an earlier filing dated 9th October 2024, the company informed that it had successfully completed the USFDA inspection for its Oncology Formulation Facility (F-2) located at Panelav. The inspection was successfully completed without any Form 483 observation.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company that has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.

The company's consolidated net profit tumbled 23.29% to Rs 138.42 crore in Q3 FY25, compared with Rs 180.45 crore posted in Q3 FY24. Revenue from operations was at Rs 1,692.74 crore in the third quarter of FY25, up 3.81% year on year (YoY).

Powered by Capital Market - Live News
   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Investor Charter | Annual Return | Account Closure | RE-KYC | Disclaimer | Feed Back | Privacy Policy | Policies & Procedures | |Rights & Obligations-English| Rights & Obligations-தமிழ் | Anti Money Laundering Policy | E-Voting | CSR | Voluntary Freezing / Blocking | Policy GTC Hit Count : 41049495
Useful Links : NSE | BSE | MCX | NSDL | CDSL | SEBI | RBI | ATTENTION INVESTOR| SMART ODR
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL Securities Private Limited